Table 1 Patient demographics and baseline characteristics (efficacy full analysis set)

Sex (women), n (%)

47.0 (77.0)

43.0 (70.5)

90 (73.8)

Age (years), mean (SD)

55.4 (10.70)

54.7 (12.16)

55.1 (11.41)

Weight (kg), mean (SD)

55.0 (12.23)

56.8 (9.71)

55.9 (11.03)

Height (cm), mean (SD)

157.9 (7.90)

158.4 (7.80)

158.1 (7.82)

BMI (kg/m²), mean (SD)

22.0 (3.98)

22.6 (3.13)

22.3 (3.58)

Disease duration (years), median (range)

5.0 (0.4–41.0)

6.3 (0.4–30.0)

5.8 (0.4–41.0)

Swollen joints (number 0–66), median (range)

11.0 (6.0–22.0)

11.0 (5.0–32.0)

11.0 (5.0–32.0)

Tender joints (number 0–68), median (range)

14.0 (6.0–56.0)

15.0 (5.0–48.0)

14.0 (5.0–56.0)

Patient’s assessment of pain (VAS; 0–10 cm), median (range)

7.4 (0.7–10.0)

7.4 (0.5–10.0)

7.4 (0.5–10.0)

Patient’s global assessment of disease activity (VAS; 0–10 cm), median (range)

7.6 (0.6–10.0)

7.1 (0.6–10.0)

7.5 (0.6–10.0)

Physician’s global assessment of disease activity (VAS; 0–10 cm), median (range)

6.5 (2.6–10.0)

6.9 (2.0–10.0)

6.6 (2.0–10.0)

HAQ-DI score (0–3), median (range)

1.4 (0.00–2.75)

1.1 (0.00–2.75)

1.3 (0.00–2.75)

CRP (mg/dl), median (range)

2.7 (0.20– 9.20)

2.5 (0.31–16.60)

2.6 (0.20–16.60)

DAS28-CRP score, median (range)

5.6 (5.14–6.11)

5.9 (4.88–6.57)

5.7 (4.93–6.29)

SDAI score, median (range)

33.2 (28.42–40.38)

38.2 (26.83–52.20)

34.7 (27.70–42.48)

CDAI score, median (range)

30.9 (24.90–37.80)

33.5 (24.20–47.40)

31.8 (24.60–38.80)

Rheumatoid factor-positive, n (%)

48 (78.7)

44 (72.1)

92 (75.4)

Anti-CCP antibody positive, n (%)

55 (90.2)

51 (83.6)

106 (86.9)